Skip to main content
Erschienen in: The Journal of Obstetrics and Gynecology of India 4/2013

01.08.2013 | Original Article

“Anti-Mullerian Hormone: Marker for Ovarian Response in Controlled Ovarian Stimulation for IVF Patients”: A First Pilot Study in the Indian Population

verfasst von: Neeta Singh, Ekta Malik, Ayan Banerjee, Kunzang Chosdol, V. Sreenivas, Suneeta Mittal

Erschienen in: The Journal of Obstetrics and Gynecology of India | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

To measure the levels of early follicular phase Anti-Mullerian hormone (AMH) in Indian patients of IVF and to evaluate the AMH as a predictive marker of ovarian response in assisted reproductive technology outcome.

Methods

Sixty women (age 25–40 years) selected for in vitro fertilization treatment were included in this study. Analysis of day-2 serum samples was done for the AMH, FSH, Inhibin B, and LH by ELISA kit methods. USG was done for the antral follicle count (AFC) and oocytes’ retrieval. Hormone parameters were compared and correlated with the oocytes’ retrieval count and the AFC. The discriminant analysis was done to compare relevance of different parameters for predicting ovarian response.

Result(s)

The Anti-Mullerian hormone showed a significant correlation with the oocytes’ retrieval after ovulation induction for IVF (r = 0.648, p < 0.0001) and no correlation was seen with serum FSH, LH, and Inhibin. Serum AMH levels show 80 % sensitivity and 80 % specificity in predicting poor ovarian response.

Conclusion(s)

There is a significant correlation between day-2 serum AMH levels and the oocytes’ retrieval count in women undergoing ovulation induction for IVF, and the AMH is a good marker as the negative predictive values for the success of ART. There is no correlation found between other hormonal ovarian reserve markers and the oocytes’ retrieval count.
Literatur
1.
Zurück zum Zitat Visser JA, de Jong FH, Laven JSE, et al. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction. 2006;131(1):1–9.PubMedCrossRef Visser JA, de Jong FH, Laven JSE, et al. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction. 2006;131(1):1–9.PubMedCrossRef
2.
Zurück zum Zitat Tremellen KP, Kolo M, Gilmore A, et al. Anti-mullerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynaecol. 2005;45(1):20–4.PubMedCrossRef Tremellen KP, Kolo M, Gilmore A, et al. Anti-mullerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynaecol. 2005;45(1):20–4.PubMedCrossRef
3.
Zurück zum Zitat Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab. 1999;84(11):4025–30.PubMedCrossRef Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab. 1999;84(11):4025–30.PubMedCrossRef
4.
Zurück zum Zitat La Marca A, Giulini S, Tirelli A, et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod. 2007;22(3):766–71.PubMedCrossRef La Marca A, Giulini S, Tirelli A, et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod. 2007;22(3):766–71.PubMedCrossRef
5.
Zurück zum Zitat Bancsi LF, Broekmans FJ, Eijkemans MJ, et al. Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril. 2002;77(2):328–36.PubMedCrossRef Bancsi LF, Broekmans FJ, Eijkemans MJ, et al. Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril. 2002;77(2):328–36.PubMedCrossRef
6.
Zurück zum Zitat Gnoth C, Schuring AN, Friol K, et al. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum Reprod. 2008;23(6):1359–65.PubMedCrossRef Gnoth C, Schuring AN, Friol K, et al. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum Reprod. 2008;23(6):1359–65.PubMedCrossRef
7.
Zurück zum Zitat Feyereisen E, Méndez Lozano DH, Taieb J, et al. Anti-Müllerian hormone: clinical insights into a promising biomarker of ovarian follicular status. Reprod Biomed Online. 2006;12(6):695–703.PubMedCrossRef Feyereisen E, Méndez Lozano DH, Taieb J, et al. Anti-Müllerian hormone: clinical insights into a promising biomarker of ovarian follicular status. Reprod Biomed Online. 2006;12(6):695–703.PubMedCrossRef
8.
Zurück zum Zitat Ebner T, Sommergruber M, Moser M, et al. Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod. 2006;21(8):2022–6.PubMedCrossRef Ebner T, Sommergruber M, Moser M, et al. Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod. 2006;21(8):2022–6.PubMedCrossRef
9.
Zurück zum Zitat Fréour T, Mirallié S, Colombel A, et al. Anti-mullerian hormone: clinical relevance in assisted reproductive therapy. Ann Endocrinol (Paris). 2006;67(6):567–74.CrossRef Fréour T, Mirallié S, Colombel A, et al. Anti-mullerian hormone: clinical relevance in assisted reproductive therapy. Ann Endocrinol (Paris). 2006;67(6):567–74.CrossRef
10.
Zurück zum Zitat Baarends WM, Hoogerbrugge JW, Post M, et al. Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression during postnatal testis development and in the adult testis of the rat. Endocrinology. 1995;136(12):5614–22.PubMedCrossRef Baarends WM, Hoogerbrugge JW, Post M, et al. Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression during postnatal testis development and in the adult testis of the rat. Endocrinology. 1995;136(12):5614–22.PubMedCrossRef
11.
Zurück zum Zitat Nikolaou D, Lavery S, Turner C, et al. Is there a link between an extremely poor response to ovarian hyperstimulation and early ovarian failure? Hum Reprod. 2002;17(4):1106–11.PubMedCrossRef Nikolaou D, Lavery S, Turner C, et al. Is there a link between an extremely poor response to ovarian hyperstimulation and early ovarian failure? Hum Reprod. 2002;17(4):1106–11.PubMedCrossRef
12.
Zurück zum Zitat Hazout A, Bouchard P, Seifer DB, et al. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82(5):1323–9.PubMedCrossRef Hazout A, Bouchard P, Seifer DB, et al. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82(5):1323–9.PubMedCrossRef
13.
Zurück zum Zitat Muttukrishna S, McGarrigle H, Wakim R, et al. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG. 2005;112(10):1384–90.PubMedCrossRef Muttukrishna S, McGarrigle H, Wakim R, et al. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG. 2005;112(10):1384–90.PubMedCrossRef
14.
Zurück zum Zitat Cook CL, Siow Y, Taylor S, et al. Serum Müllerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril. 2000;73(4):859–61.PubMedCrossRef Cook CL, Siow Y, Taylor S, et al. Serum Müllerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril. 2000;73(4):859–61.PubMedCrossRef
Metadaten
Titel
“Anti-Mullerian Hormone: Marker for Ovarian Response in Controlled Ovarian Stimulation for IVF Patients”: A First Pilot Study in the Indian Population
verfasst von
Neeta Singh
Ekta Malik
Ayan Banerjee
Kunzang Chosdol
V. Sreenivas
Suneeta Mittal
Publikationsdatum
01.08.2013
Verlag
Springer India
Erschienen in
The Journal of Obstetrics and Gynecology of India / Ausgabe 4/2013
Print ISSN: 0971-9202
Elektronische ISSN: 0975-6434
DOI
https://doi.org/10.1007/s13224-012-0318-6

Weitere Artikel der Ausgabe 4/2013

The Journal of Obstetrics and Gynecology of India 4/2013 Zur Ausgabe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Welche Übungen helfen gegen Diastase recti abdominis?

30.04.2024 Schwangerenvorsorge Nachrichten

Die Autorinnen und Autoren einer aktuellen Studie aus Griechenland sind sich einig, dass Bewegungstherapie, einschließlich Übungen zur Stärkung der Bauchmuskulatur und zur Stabilisierung des Rumpfes, eine Diastase recti abdominis postpartum wirksam reduzieren kann. Doch vieles ist noch nicht eindeutig belegt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.